imatinib mesylate has been researched along with Vascular Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aman, J; Peters, MJ; van Nieuw Amerongen, GP; Vonk Noordegraaf, A; Weenink, C | 1 |
| Aguiar, JM; Brümmendorf, TH; Cortes, JE; Dimitrov, S; Durand, JB; Fly, KD; Gambacorti-Passerini, C; Jean Khoury, H; Kantarjian, H; Leip, E; Lipton, JH; Matczak, E; Mauro, MJ; Pavlov, D; Shapiro, M | 1 |
| Chatelain, C; Dogné, JM; Douxfils, J; Graux, C; Haguet, H; Mullier, F | 1 |
| Bilmes, R; Lin, J; Lingohr-Smith, M; Makenbaeva, D | 1 |
| Grimminger, F; Schermuly, RT | 1 |
| Cortes, J; Kantarjian, H; Quintás-Cardama, A | 1 |
| Häyry, P; Savikko, J; Von Willebrand, E | 1 |
2 review(s) available for imatinib mesylate and Vascular Diseases
| Article | Year |
|---|---|
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Vascular Diseases | 2017 |
PDGF receptor and its antagonists: role in treatment of PAH.
Topics: Animals; Benzamides; Clinical Trials as Topic; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Vascular Diseases | 2010 |
1 trial(s) available for imatinib mesylate and Vascular Diseases
| Article | Year |
|---|---|
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aniline Compounds; Cardiotoxicity; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinolines; Retrospective Studies; Risk Factors; Vascular Diseases; Young Adult | 2016 |
4 other study(ies) available for imatinib mesylate and Vascular Diseases
| Article | Year |
|---|---|
Reversal of vascular leak with imatinib.
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pulmonary Edema; Pyrimidines; Vascular Diseases | 2013 |
Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dasatinib; Female; Health Services; Humans; Imatinib Mesylate; Insurance Claim Review; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Economic; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Vascular Diseases; Young Adult | 2017 |
Nilotinib-associated vascular events.
Topics: Aged; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Risk Factors; Vascular Diseases | 2012 |
Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection.
Topics: Alkynes; Angiogenesis Inhibitors; Animals; Benzamides; Blood Vessels; Constriction, Pathologic; Dihydroorotate Dehydrogenase; Graft Rejection; Imatinib Mesylate; Immunosuppressive Agents; Isoxazoles; Male; Nitriles; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Wistar; Recurrence; Tunica Intima; Uridine; Vascular Diseases | 2003 |